Stock comparison

ABBVvsBIIB

AbbVie IncvsBiogen Inc. Real data pulled from the alphactor.ai fundamentals pipeline — valuation, balance-sheet health, momentum, and analyst sentiment side by side.

ABBV

AbbVie Inc

$200.95

-12.05%

Biotechnology$362.8BNYSE

BIIB

Biogen Inc

$187.88

+6.91%

Biotechnology$25.8BNASDAQ

60-day price, rebased to 100

ABBV -8.25% · BIIB +6.64%

Round-by-round

ABBV 3·BIIB 3

EdgeBIIB

Valuation upside

-48.60% vs +7.40% to DCF fair value

EdgeBIIB

Balance-sheet strength

Altman Z 2.25 vs 3.10

EdgeABBV

Fundamental quality

Piotroski 7.00 vs 6.00 (of 9)

EdgeABBV

Growth + margins

Rule-of-40 37.70 vs 23.00

EdgeBIIB

60-day momentum

-8.25% vs +6.64% price return

EdgeABBV

Market-cap liquidity

$362.8B vs $25.8B

Verdict

Across6categories,the two names are evenly matched —3wins each. Neither score is a buy signal on its own: run the full backtest and credibility tests on alphactor.ai before putting money on it.

Backtest a strategy onABBVorBIIB

Point-in-time backtests, 8-layer credibility pipeline, conviction scoring — free to start.